Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

David N. Sedloev, Qian Chen, Julia M. Unglaub, Anita Schmitt, Carsten Müller-Tidow, Michael Schmitt, Tim Sauer

Blood (2024) 144 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2024-210286

Published: 2024

Journal Articles

Characterizing Environmental Adaption and Virulence of Gut Microbiome Enterococcus Spp. from Patients Receiving CD19-Targeted CAR-T Cell Therapy

Niklas Deschl, Viktoria Blumenberg, Maria-Luisa Schubert, Anita Schmitt, Michael Schmitt, Marion Subklewe, Christoph Stein-Thoeringer

Blood (2024) 144 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2024-205390

Published: 2024

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Julia M. Unglaub, Berit Brinkmann, Qian Chen, David Sedloev, Peter-Martin Bruch, Carolin Kolb, Volker Eckstein, Yi Liu, Anita Schmitt, Simon Raffel, Michael Schmitt, Carsten Müller-Tidow, Junyan Lu, Sascha Dietrich, Tim Sauer

Blood (2023) 142 (Supplement 1): 5969.

https://doi.org/10.1182/blood-2023-181251

Published: 2023

Journal Articles

Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Yuntian Ding, Lei Wang, Ming Ni, Wenjie Gong, Sanmei Wang, Brigitte Neuber, Maria-Luisa Schubert, Tim Sauer, Angela Hückelhoven-Krauss, Thomas Luft, Ute Hegenbart, Stefan Schönland, Volker Eckstein, Jishi Wang, William Hermann Krüger, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt

Blood (2021) 138 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2021-150106

Published: 2021

Journal Articles

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Maria-Luisa Schubert, Anita Schmitt, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, Birgit Michels, Philip Waldhoff, Leopold Sellner, Felix Korell, Susanne Hofmann, Petra Pavel, Anthony D Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt

Blood (2021) 138 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2021-152028

Published: 2021

Journal Articles

Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy

Felix Korell, Maria-Luisa Schubert, Tim Sauer, Anita Schmitt, Patrick Derigs, Tim Frederik Weber, Paul Schnitzler, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt

Blood (2021) 138 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2021-149743

Published: 2021

Journal Articles

The First Real-World Experience with Betibeglogene Autotemcel (beti-cel) Gene Therapy Treatment for Transfusion-Dependent β-Thalassemia (TDT)

Joachim B. Kunz, Eva Roth, Adil Mirza, Johann Greil, Petra Pavel, Anita Schmitt, Michael Schmitt, Alexander Kunz, Andreas E. Kulozik

Blood (2021) 138 (Supplement 1): 4917.

https://doi.org/10.1182/blood-2021-148460

Published: 2021

Journal Articles

CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

Nicola Schanda, Alexander Kunz, Tim Sauer, Maria-Luisa Schubert, Felix Korell, Angela Hückelhoven-Krauss, Brigitte Neuber, Mandy Hinkelbein, Carsten Müller-Tidow, Michael Schmitt, Anita Schmitt

Blood (2021) 138 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2021-152955

Published: 2021

Journal Articles

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Felix Korell, MD, Thomas Luft, MD, PhD, Michael Schmitt, MD, Sascha Dietrich, MD, Anita Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139615

Published: 2020

Journal Articles

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Bailin He, PhD, Lei Wang, MD, Brigitte Neuber, Anita Schmitt, MD, Niclas Kneisel, PhD, Thomas Hoeger, PhD, Carsten Mueller-Tidow, MD, Michael Schmitt, MD, Susanne Hofmann, MD

Blood (2019) 134 (Supplement_1): 3226.

https://doi.org/10.1182/blood-2019-122833

Published: 2019

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Mingya Yang, MD, Lei Wang, MD, Ming Ni, Maria-Luisa Schubert, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Ruben A. Gößmann, Christian Kleist, Volker Eckstein, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 5620.

https://doi.org/10.1182/blood-2019-125622

Published: 2019

Journal Articles

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

Ruben A. Gößmann, Lei Wang, MD, Ming Ni, Mingya Yang, MD, Thomas Luft, Ute Hegenbart, MD, Stefan O. Schönland, MD, Patrick Wuchter, MD, Volker Eckstein, William Hermann Krüger, MD PhD, Ronit Yerushalmi, MD, Katia Beider, Arnon Nagler, MD MSc, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 3287.

https://doi.org/10.1182/blood-2019-125049

Published: 2019

Journal Articles

No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy

Blood (2018) 132 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2018-99-113277

Published: 2018

Journal Articles

Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion — a Phase I Study (TOL-1)

Christian Morath, MD, Anita Schmitt, MD, Christian Kleist, PhD, Volker Daniel, MD, Gerhard Opelz, MD, Caner Süsal, MD, Florian Kälble, MD, Claudia Sommerer, MD, Lei Wang, MD, Angela Hückelhoven, PhD, Arianeb Mehrabi, MD, Uta Merle, MD, Luiza Pego da Silva, Carsten Müller-Tidow, MD, Martin Zeier, MD, Matthias Schaier, MD, Michael Schmitt, MD PhD, Peter Terness, MD

Blood (2018) 132 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2018-99-113386

Published: 2018

Journal Articles

Development of Potency Assays for Quality Assessment of an Advanced Therapy Medicinal Product: Mitomycin C-Induced Peripheral Blood Mononuclear Cell (MIC) Product

Ming NI, Lei Wang, MD, Christian Kleist, PhD, Peter Terness, MD, Gerhard Opelz, MD, Christian Morath, MD, Matthias Schaier, MD, Carsten Müller-Tidow, MD, Martin Zeier, MD, Michael Schmitt, MD PhD, Anita Schmitt, MD

Blood (2018) 132 (Supplement 1): 5689.

https://doi.org/10.1182/blood-2018-99-113337

Published: 2018

Journal Articles

Biomarkers for Clinical Response of Extracorporeal Photopheresis

Blood (2017) 130 (Supplement 1): 3264.

https://doi.org/10.1182/blood.V130.Suppl_1.3264.3264

Published: 2017

Journal Articles

PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells

Sophia Stock, Jean-Marc Hoffmann, Lei Wang, MD, Wenjie Gong, Angela Hückelhoven, PhD, Brigitte Neuber, PhD, Maria-Luisa Schubert, MD, Ulrike Gern, Anita Schmitt, MD, Carsten Müller-Tidow, Peter Dreger, MD, Michael Schmitt, MD PhD, Leopold Sellner, MD

Blood (2017) 130 (Supplement 1): 3194.

https://doi.org/10.1182/blood.V130.Suppl_1.3194.3194

Published: 2017

Journal Articles

Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

Jean-Marc Hoffmann, Lei Wang, Angela Hückelhoven, PhD, Anita Schmitt, MD, Ulrike Gern, Leopold Sellner, MD, Christian Kleist, PhD, Jessica Wenthe, Patrick Wuchter, MD, Maria-Luisa Schubert, MD, Hyeon Joo Yoo, Ming Ni, Susanne Hofmann, MD, Peter Dreger, MD, Anthony D. Ho, MD, Angelica Loskog, PhD, Michael Schmitt, MD

Blood (2016) 128 (22): 3509.

https://doi.org/10.1182/blood.V128.22.3509.3509

Published: 2016

NARROW

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

Characterizing Environmental Adaption and Virulence of Gut Microbiome Enterococcus Spp. from Patients Receiving CD19-Targeted CAR-T Cell Therapy

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy

The First Real-World Experience with Betibeglogene Autotemcel (beti-cel) Gene Therapy Treatment for Transfusion-Dependent β-Thalassemia (TDT)

CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy

Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion — a Phase I Study (TOL-1)

Development of Potency Assays for Quality Assessment of an Advanced Therapy Medicinal Product: Mitomycin C-Induced Peripheral Blood Mononuclear Cell (MIC) Product

Biomarkers for Clinical Response of Extracorporeal Photopheresis

PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells

Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only